Valuation as at 2026-08-14 · see also the S&P 500 Most Undervalued screen
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Johnson & Johnson JNJ
Healthcare · Drug Manufacturers - General
Johnson & Johnson's price & financial trends
Each card is labelled with its own reporting period — quarterly where Yahoo provides it for this market, annual otherwise.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per quarter
Free cash flow Per quarter
Dividend per share Per quarter
Value investing scale · Buffett · Dalio · Graham
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 1.4% | 2.9% | 4.3% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 6.81% | 5.81% | 4.81% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.68% + 0.23 × 5.50% = 5.95% · WACC = weighted by 93%/7% capital structure
These numbers come from running Johnson & Johnson's cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or JNJ's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with JNJ →
More S&P 500 stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the S&P 500 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is Johnson & Johnson (JNJ) undervalued?
The Base-case DCF estimates intrinsic value at $207.56 vs a price of $262.08 on 2026-08-14 — a -20.8% margin, so the Base case reads overvalued. This is a mechanical output, not advice.